OK, now that I’ve got those thoughts from yesterday off my chest, I have an investment idea that’s relevant. It’s Medifast (MED), the purveyor of pre-packaged portion-controlled meals. The primary market for its products is people who want to lose weight; a secondary and overlapping market is people who want to control Type 2 diabetes. Back on August 17, when the stock was selling at 15, it earned a spot in Cabot Top Ten Report, and here’s some of what editor Mike Cintolo wrote: “In recent weeks, we’ve twice seen nutrition supplements juggernaut NBTY in Cabot Top Ten Report...
